Press Release

<< Back
Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Conferences in March 2017

BOSTON, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc., (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentations at the following investor healthcare conferences:

Raymond James 38th Annual Institutional Investors Conference
Presenter: Scott Holmes, SVP and Chief Financial Officer
Presentation Date: Tuesday, March 7, 2017
Presentation Time: 8:40 a.m. ET

37th Annual Cowen and Company Healthcare Conference
Presenter: Greg Madison, President and Chief Executive Officer
Presentation Date: Wednesday, March 8, 2017
Presentation Time: 10:00 a.m. ET

Live audio webcasts of the presentations will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.

KERYX BIOPHARMACEUTICALS CONTACT:
Lora Pike
Senior Director, Investor Relations
T: 617-466-3511
lora.pike@keryx.com

Primary Logo

Keryx Biopharmaceuticals, Inc.